Frontiers | EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies | Oncology
Erlotinib Directly Inhibits HER2 Kinase Activation and Downstream Signaling Events in Intact Cells Lacking Epidermal Growth Factor Receptor Expression | Cancer Research
Tackling Drug Resistance in EGFR Exon 20 Insertion Mutant Lung Cancer | PGPM
Non-small cell lung cancer-small cell lung cancer transformation as mechanism of resistance to tyrosine kinase inhibitors in lung cancer
Mechanism of acquired T790m mutation and action of 3rd generation EGFR... | Download Scientific Diagram
Dacoplice® | Pfizer India | Mechanism of action
Mechanisms of acquired resistance to gefitinib/erlotinib in... | Download Scientific Diagram
Oncogenic drivers in nonsmall cell lung cancer and resistance to epidermal growth factor receptor tyrosine kinase inhibitors
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer | European Respiratory Society
Repeat biopsy procedures and T790M rates after afatinib, gefitinib, or erlotinib therapy in patients with lung cancer - Lung Cancer
Erlotinib | SpringerLink
Figure 1 from Current Adjuvant Therapeutic Approaches for Pancreatic Cancer | Semantic Scholar
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer | Signal Transduction and Targeted Therapy
Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer | Clinical Cancer Research
Mechanisms of resistance to EGFR tyrosine kinase inhibitors - ScienceDirect
InOncology - Afatinib NSCLC Treatment | Information | Boehringer Ingelheim
Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer
Mechanisms of EGFR inhibitor resistance and therapeutic strategies. | Download Scientific Diagram
Erlotinib - Drugs Details
Identification of Ketene-Reactive Intermediate of Erlotinib Possibly Responsible for Inactivation of P450 Enzymes | Drug Metabolism & Disposition
Cancers | Free Full-Text | Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment | HTML
Action mechanism of epidermal growth factor receptor-tyrosine kinase... | Download Scientific Diagram
PLOS ONE: Mechanism of Resistance and Novel Targets Mediating Resistance to EGFR and c-Met Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer
Mechanisms of resistance to EGFR tyrosine kinase inhibitors - ScienceDirect
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pha
Mechanisms of action of EGFR inhibitors | EGFR Inhibitors in Cancer Treatment
Critical appraisal of the role of gefitinib in the management of local | OTT
Tarceva ( erlotinib )
Figure 1 from Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells. | Semantic Scholar
